Addex and Indivior select candidates from collaboration

Swiss biopharma Addex Therapeutics and US specialty pharma Indivior have announced the selection of clinical candidates from their gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM) research collaboration.

Indivior has selected a compound for future development in substance use disorder and will now undertake all future development of this drug. 

Under the terms of the agreement, Addex is eligible for payment of up to $330 million on successful achievement of prespecified regulatory, clinical and commercial milestones, as well as tiered royalties on the level of net sales from high single digits up to low double-digit.